Skip to main content
Erschienen in: Journal of Cachexia, Sarcopenia and Muscle 2/2014

01.06.2014 | Original Article

Patients’ rationale for declining participation in a cancer-associated weight loss study

verfasst von: Tammy Wanger, Nathan R. Foster, Phuong L. Nguyen, Aminah Jatoi

Erschienen in: Journal of Cachexia, Sarcopenia and Muscle | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Fewer than 5 % of cancer patients participate in clinical research. Although this paltry rate has led to extensive research on this topic, previous studies have not sought verbatim comments in a real-time, comprehensive manner to understand why patients decline.

Methods

This study used a low-risk, non-interventional parent study that focused on cancer-associated weight loss to understand patients’ reasons for declining research participation. A research assistant wrote down the name and verbatim reason of all patients who declined to participate. These comments with accompanying patient demographic data are the subject of this report.

Results

Of the 334 patients, 51 (15 %) declined parent study enrollment; three comment-related themes emerged: (1) a repelling sense of too much institutional research, (2) overwhelming personal health issues, and (3) a low likelihood of returning to the institution. In univariate and multivariate analyses, only age (older) and gender (female) were associated with non-enrollment. Interestingly, 41 patients with fatigue scores of 7 or worse and 26 with pain scores of 7 or worse were enrolled.

Conclusions

Although many factors were associated with declining to participate in research, symptom severity was not. Upfront education might help cancer patients better prioritize their participation in research, particularly as some patients felt overwhelmed by too much research in the institution; and for now, investigators should continue to keep asking patients for their participation.
Literatur
1.
Zurück zum Zitat Klabunde CN, Keating NL, Potosky AL, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst February 22, 2011 Klabunde CN, Keating NL, Potosky AL, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst February 22, 2011
3.
Zurück zum Zitat Fouad MN, Lee JY, Catalano PJ, et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract. 2013;9:e40–7.PubMedCentralPubMedCrossRef Fouad MN, Lee JY, Catalano PJ, et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract. 2013;9:e40–7.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Horn L, Keedy VL, Campbell N, et al. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer. 2013;14:14–8.PubMedCrossRef Horn L, Keedy VL, Campbell N, et al. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer. 2013;14:14–8.PubMedCrossRef
5.
Zurück zum Zitat Bierrzycki BA. Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum. 2011;38:542–52.CrossRef Bierrzycki BA. Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum. 2011;38:542–52.CrossRef
6.
Zurück zum Zitat Yang ZJ, McCopmas KA, Gay GK, et al. Comparing decision making between cancer patients and the general population: thoughts, emotions, and social influence? J Health Commun. 2012;17:477–94.PubMedCrossRef Yang ZJ, McCopmas KA, Gay GK, et al. Comparing decision making between cancer patients and the general population: thoughts, emotions, and social influence? J Health Commun. 2012;17:477–94.PubMedCrossRef
7.
Zurück zum Zitat Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials. Oncologist. 2012;17:1180–90.PubMedCentralPubMedCrossRef Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials. Oncologist. 2012;17:1180–90.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Ford M, Wahlquist A, Blake R, et al. Assessing an intervention to improve clinical trial perceptions among predominantly African-American communities in South Carolina. Prog Commun Health Partnership. 2012;6:249–63.CrossRef Ford M, Wahlquist A, Blake R, et al. Assessing an intervention to improve clinical trial perceptions among predominantly African-American communities in South Carolina. Prog Commun Health Partnership. 2012;6:249–63.CrossRef
9.
Zurück zum Zitat Penberthy L, Brown R, Wilson-Genderson M, et al. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials. 2012;9:788–97.PubMedCrossRef Penberthy L, Brown R, Wilson-Genderson M, et al. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials. 2012;9:788–97.PubMedCrossRef
10.
Zurück zum Zitat Gerber DE, Rasco DW, Skinner CS, et al. Consent timing and experience: modifiable factors that may influence interest in clinical research. JOP. 2012;8:91–6.PubMedCentralPubMed Gerber DE, Rasco DW, Skinner CS, et al. Consent timing and experience: modifiable factors that may influence interest in clinical research. JOP. 2012;8:91–6.PubMedCentralPubMed
11.
Zurück zum Zitat Mazanec S, Daly B, Meropol NJ, Step M. Facilitating enrollment in a cancer registry through modified consent procedures. J Empir Res Hum Res Ethics. 2012;7:71–5.PubMedCrossRef Mazanec S, Daly B, Meropol NJ, Step M. Facilitating enrollment in a cancer registry through modified consent procedures. J Empir Res Hum Res Ethics. 2012;7:71–5.PubMedCrossRef
12.
Zurück zum Zitat Jacobs SR, Weiner BJ, Minasian LM, Good MJ. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program. Contemp Clin Trials. 2013;34:320–5.PubMedCentralPubMedCrossRef Jacobs SR, Weiner BJ, Minasian LM, Good MJ. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program. Contemp Clin Trials. 2013;34:320–5.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Barnhill RL, Piepkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dematol. 1998;134:991–4.CrossRef Barnhill RL, Piepkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dematol. 1998;134:991–4.CrossRef
14.
Zurück zum Zitat Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815–21.PubMedCentralPubMed Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815–21.PubMedCentralPubMed
15.
Zurück zum Zitat Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17:643–53.PubMedCrossRef Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17:643–53.PubMedCrossRef
16.
Zurück zum Zitat Chow CJ, Habemann EB, Abraham A, et al. Does enrollment in cancer trials improve survival? J An Coll Surg. 2013;21:774–80.CrossRef Chow CJ, Habemann EB, Abraham A, et al. Does enrollment in cancer trials improve survival? J An Coll Surg. 2013;21:774–80.CrossRef
17.
Zurück zum Zitat Schwentner L, Van Ewijk R, Kurzeder C, et al. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49:553–63.PubMedCrossRef Schwentner L, Van Ewijk R, Kurzeder C, et al. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49:553–63.PubMedCrossRef
18.
Zurück zum Zitat Sloan JA, Aaronson N, Cappelleri JC, et al. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479–87.PubMedCrossRef Sloan JA, Aaronson N, Cappelleri JC, et al. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479–87.PubMedCrossRef
22.
23.
Zurück zum Zitat Jenkins V, Farewell D, Batt L, et al. The attitudes of 1066 patients with cancer towards participation in randomized clinical trials. Br J Cancer. 2010;103:1801–7.PubMedCentralPubMedCrossRef Jenkins V, Farewell D, Batt L, et al. The attitudes of 1066 patients with cancer towards participation in randomized clinical trials. Br J Cancer. 2010;103:1801–7.PubMedCentralPubMedCrossRef
Metadaten
Titel
Patients’ rationale for declining participation in a cancer-associated weight loss study
verfasst von
Tammy Wanger
Nathan R. Foster
Phuong L. Nguyen
Aminah Jatoi
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cachexia, Sarcopenia and Muscle / Ausgabe 2/2014
Print ISSN: 2190-5991
Elektronische ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-014-0128-z

Weitere Artikel der Ausgabe 2/2014

Journal of Cachexia, Sarcopenia and Muscle 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.